Drug Profile
Kanglaite - Zhejiang Kanglaite Pharmaceutical/KangLaiTe USA
Alternative Names: Kanglaite gelcap; Kanglaite injection; KLT; KLTc; KLTiLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator KangLaiTe USA; Zhejiang Kanglaite Pharmaceutical
- Class Antineoplastics; Herbal medicines; Traditional Chinese medicine
- Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants; Cell cycle inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cachexia; Cancer; Liver cancer; Non-small cell lung cancer
- Phase II Pancreatic cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cachexia in USA (IV, Injection)
- 19 Aug 2015 Phase-II development for Pancreatic cancer and Prostate cancer is ongoing in USA
- 01 Nov 2012 Discontinued - Phase-II for Non-small cell lung cancer in USA (IV)